Companies developing and selling oncology drugs are facing a severe logistics obstacle after the National Pharmaceutical Pricing Authority’s (NPPA) trade margin rationalization (TMR) directive. Reporting from Chennai on October 26, 2026, Peethaambaran Kunnathoor notes that the abrupt rollout has caused an operational crunch, impacting regulatory compliance, supply chain, and legal teams alike as businesses attempt to align with complicated financial rules and tight administrative timelines.
Tight deadlines and complex calculations
Companies have been given a seven-day window to submit detailed price revisions, a task that typically takes weeks. This involves gathering and validating net sales realizations, invoice metrics, and transaction data to determine baseline prices for March 2026 or an extended 12-month period. Industry regulatory heads emphasize that this process requires meticulous validation across distribution channels, further complicating the task. The mandatory filing requirement applies universally, forcing companies to recalculate prices based on historical sales realizations, even if no downward revision is needed. Additionally, newly launched non-scheduled anti-cancer drugs must calculate ceiling prices using current data, adding another layer of complexity to the workload.
Operational hurdles and supply chain challenges
The regulatory framework demands proof of stakeholder communication, including public notices in leading national newspapers and website updates, all within the same seven-day period. Supply chain executives highlight the difficulty of re-labeling thousands of stock-keeping units, recalling shipments, and updating price lists via the IPDMS portal before the November 9 effective date. Companies must also provide batch-wise production details and distributor inventory reports to ensure price reductions are passed down the trade pipeline. The NPPA’s requirement to maintain current production levels and seek approval for any changes adds further complexity, as manufacturers must adhere to strict continuity mandates.
Impact on patient assistance programs and smaller companies
To maintain Patient Assistance Programs (PAPs), companies face exhaustive audit requirements, including detailed record-keeping of patient identities, diagnoses, and caregiver documentation. This exposes them to legal liability under the Essential Commodities Act, 1955, as any discrepancies can result in penalties. Manufacturers must submit formal undertakings to the NPPA, adhering to Department of Revenue customs guidelines, and maintain records of patient names, ages, addresses, verified ID proofs, diagnostic notes, and exact consumption quantities. Industry bodies warn that smaller companies may struggle to absorb these compliance costs and potential liabilities, potentially leading to temporary suspension of distribution lines. This disruption could impact the availability of critical cancer treatments, disproportionately affecting smaller players and patient access to essential medications.
